Chemical Research in 2923-28-6

This literature about this compound(2923-28-6)Safety of Silver(I) trifluoromethanesulfonatehas given us a lot of inspiration, and I hope that the research on this compound(Silver(I) trifluoromethanesulfonate) can be further advanced. Maybe we can get more compounds in a similar way.

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Evidence in primates supporting the use of chemogenetics for the treatment of human refractory neuropsychiatric disorders, published in 2021-12-01, which mentions a compound: 2923-28-6, Name is Silver(I) trifluoromethanesulfonate, Molecular CAgF3O3S, Safety of Silver(I) trifluoromethanesulfonate.

Non-human primate (NHP) models are essential for developing and translating new treatments that target neural circuit dysfunction underlying human psychopathol. As a proof-of-concept for treating neuropsychiatric disorders, we used a NHP model of pathol. anxiety to investigate the feasibility of decreasing anxiety by chemogenetically (DREADDs [designer receptors exclusively activated by designer drugs]) reducing amygdala neuronal activity. Intraoperative MRI surgery was used to infect dorsal amygdala neurons with AAV5-hSyn-HA-hM4Di in young rhesus monkeys. In vivo microPET studies with [11C]-deschloroclozapine and postmortem autoradiog. with [3H]-clozapine demonstrated selective hM4Di binding in the amygdala, and neuronal expression of hM4Di was confirmed with immunohistochem. Addnl., because of its high affinity for DREADDs, and its approved use in humans, we developed an individualized, low-dose clozapine administration strategy to induce DREADD-mediated amygdala inhibition. Compared to controls, clozapine selectively decreased anxiety-related freezing behavior in the human intruder paradigm in hM4Di-expressing monkeys, while coo vocalizations and locomotion were unaffected. These results are an important step in establishing chemogenetic strategies for patients with refractory neuropsychiatric disorders in which amygdala alterations are central to disease pathophysiol.

This literature about this compound(2923-28-6)Safety of Silver(I) trifluoromethanesulfonatehas given us a lot of inspiration, and I hope that the research on this compound(Silver(I) trifluoromethanesulfonate) can be further advanced. Maybe we can get more compounds in a similar way.

Reference:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem